Collaboration

NeoClone is actively seeking partners to develop new antibodies on the strength of its ABL-MYC process. We rely on researchers to identify opportunities for promising antibodies. We want to act on these opportunities with an approach that is win-win for both parties.

These arrangements can take many forms. If you have unique antigens, NeoClone will develop the mAb with significant discounts in return for exclusive or preferred terms for use of the mAbs in our catalog. You will also receive a royalty tied to future sales of the mAb. Our goal is to reach the research community with high quality, desired mAbs priced competitively across a broad spectrum of areas.

Alternatively, if you are interested in developing a diagnostic or therapeutic product, we can provide needed development services at discounted levels in return for some share of your downstream revenue.

NeoClone has a strong believe that shared risk, shared benefit is a great foundation for enduring partnerships with collaborators. Let us show you how this can work to your benefit.

To learn more, please contact:

Randall Wagner
NeoClone Biotechnology
1202 Ann Street
Madison, WI 53713

608-260-8190 (phone)
608-260-8192 (fax)
rwagner@neoclone.com